Compare iShares MSCI India ETF (INDA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Tempus AI — how do they compare? iShares MSCI India ETF trades at $46.11 (market cap $5.81B), while Tempus AI trades at $70.35 (market cap $12.77B). The key difference: Tempus AI is far larger — about 2.2× iShares MSCI India ETF's market cap, and Tempus AI is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 57 Days and Tempus AI for 22 Days on average.
| INDA | TEM | |
|---|---|---|
Market Cap | $5.81B | $12.77B |
Volume | 5,590,429 | 8,980,490 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $55.29 | $99.28 |
52-Week Low | $45.42 | $41.55 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | — | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA is trading at $46.12, down 1.31% with a bearish technical signal across moving averages and oscillators. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Technical indicators show oversold conditions with RSI readings below 30, while support and resistance cluster around $46.
The outlook remains cautious given India's infrastructure constraints and global trade tensions. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy security concerns, weather-related agricultural impacts, and IT sector weakness. Current technical oversold conditions may present entry points for patient investors.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
